lumigan: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Abbvie	LUMIGAN	bimatoprost	SOLUTION/DROPS;OPHTHALMIC	022184	NDA	Allergan, Inc.	0023-3205-02	1 BOTTLE, DROPPER in 1 CARTON (0023-3205-02) / 2.5 mL in 1 BOTTLE, DROPPER	2010-09-10
Abbvie	LUMIGAN	bimatoprost	SOLUTION/DROPS;OPHTHALMIC	022184	NDA	Allergan, Inc.	0023-3205-03	1 BOTTLE, DROPPER in 1 CARTON (0023-3205-03) / 2.5 mL in 1 BOTTLE, DROPPER	2010-09-10
Abbvie	LUMIGAN	bimatoprost	SOLUTION/DROPS;OPHTHALMIC	022184	NDA	Allergan, Inc.	0023-3205-05	1 BOTTLE, DROPPER in 1 CARTON (0023-3205-05) / 5 mL in 1 BOTTLE, DROPPER	2010-09-10
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: April 26, 2026

LUMIGAN (bimatoprost) suppliers and supply chain mapping

LUMIGAN is the brand for bimatoprost (a prostaglandin analog used primarily for ocular hypertension and open-angle glaucoma). Supplier identification for branded ophthalmic products depends on what you mean by “supplier”: (1) the active pharmaceutical ingredient (API) manufacturer of bimatoprost, (2) the finished-dose manufacturer of the ophthalmic solution, or (3) the packaging/distribution entities. Without those scoping rules, supplier lists can mix roles and mislead procurement and IP diligence.

To stay actionable, the supplier set below is limited to entities that are consistently tied to bimatoprost commercialization and/or product manufacturing across regulated markets, using public labeling and regulatory documentation.

Who supplies LUMIGAN in practice?

1) API suppliers for bimatoprost

The bimatoprost market uses contract and in-house routes for API and sterile manufacturing. In global ophthalmics supply chains, API procurement typically comes from specialized steroid/prostaglandin-process chemistry firms, often under confidentiality agreements that prevent naming in public branding labels.

Publicly verifiable API supplier names are not consistently disclosed on LUMIGAN product labels. As a result, API supplier identification must be derived from regulatory filings (e.g., US DMFs/Canadian filings), country-specific regulatory databases, and commercial contract manufacturing directories.

Actionable constraint: any “API supplier list” built from non-regulatory third-party directories risks role confusion (finished dose vs. API) and data drift. This response therefore does not assert specific bimatoprost API manufacturer names unless they are directly tied to LUMIGAN manufacturing or are explicitly documented in accessible regulatory/label records.

2) Finished-dose manufacturers and packagers

Finished-dose ophthalmic solutions require aseptic manufacturing, sterile filtration/fill, container-closure controls, and label/packaging under controlled quality systems.

In the ophthalmic category, the finished-dose manufacturer is often a contract sterile manufacturer or the branded marketer’s affiliate, with packaging sometimes handled by a separate entity.

Public LUMIGAN labeling does not universally list the fill-finish site across all markets, and sites vary by country and through time.

3) Marketer/distributor (commercial supply owner)

The branded marketer/distributor is the most stable “supplier” for commercial procurement:

AbbVie historically owns LUMIGAN in key markets (through Allergan legacy structures).
Distribution is handled via AbbVie’s commercial operations and licensed distributors in each geography.

What the manufacturer/distributor footprint looks like by market

US

For the US, LUMIGAN is marketed under the AbbVie/Allergan brand structure. Retail/wholesale supply is routed via AbbVie distribution channels.

EU/UK

In Europe, LUMIGAN is commonly distributed under Allergan/AbbVie legal entities, with local distributors depending on national licensing.

Canada

Canada follows the same legacy brand structure, with AbbVie Canada commercial distribution.

Procurement implication: If your intent is to identify “who to pay,” the contract counterparty for purchase is usually the marketer/distributor chain. If your intent is IP diligence or technology sourcing, you must map fill-finish and API process ownership from regulatory filings, not from packaging inserts.

Evidence baseline from public sources

The most reliable public “supplier” identifiers for LUMIGAN are found in:

Product labeling that names the MAH (marketing authorization holder) and sometimes the manufacturer/packer
Regulatory submissions and product monographs (where accessible), which list manufacturing sites for the finished dose
US and other jurisdictions’ drug master file references (DMF) that identify API sources for bimatoprost

However, the exact list of bimatoprost API suppliers and sterile fill-finish sites is not consistently exposed in the visible label text alone. Any attempt to enumerate API suppliers without regulatory crosswalks would risk factual errors.

Operational guidance for supplier due diligence (procurement and IP)

If your goal is sourcing (commercial procurement)

Confirm the MAH/legal entity on the specific country carton and insert.
Confirm the NDC/strength/form (LUMIGAN 0.01% vs other strengths, and packaging format).
Use the local regulatory label’s manufacturer/packager section as the first-tier supplier list.
For reliability, request Certificate of Analysis (CoA) and GMP compliance attestations from the vendor before procurement.

If your goal is IP and freedom-to-operate (FTO)

Map the API chain from bimatoprost DMFs (US) or equivalent API references (EU national/regional submissions).
Map the finished-dose chain from the product’s manufacturing site listing in regulatory authorizations.
Cross-check whether the generic entrant uses the same API source and whether fill-finish is done by the same sterile contractor.

Key tables

Table 1: Supplier role taxonomy for LUMIGAN

Supply layer	Typical entity type	What “supplier” means operationally	Public label visibility
API (bimatoprost)	API contractor/manufacturer	Who produces active	Often not named
Finished dose (sterile fill-finish)	Aseptic sterile contractor or in-house site	Who makes drug product	Sometimes named, often by market
Marketing authorization holder / distributor	AbbVie/Allergan affiliate	Who owns commercialization and sells	Usually named
Packaging/labeling	Secondary contractor	Who packages cartons/bottles	Sometimes named, market-dependent

Table 2: “Most stable” supplier identity

Entity	Role	Stability across time/regions	Procurement relevance
AbbVie (Allergan legacy)	Branded marketer/distributor	High	Determines commercial purchase counterparty
Local MAH affiliate	Local authorization/distribution entity	Medium	Determines local regulatory and invoicing channel
Sterile fill-finish site	Manufacturer of drug product	Medium to low	Determines GMP pedigree and tech transfer risk
API manufacturer	Manufacturer of bimatoprost	Medium to low	Determines DMF/IP chain mapping

Key Takeaways

LUMIGAN’s “supplier” answer is role-dependent. AbbVie (Allergan legacy) is the most stable commercial supplier identity (marketer/distributor).
API suppliers of bimatoprost are not reliably disclosed on LUMIGAN labels and vary by jurisdiction and time, making regulatory-filings mapping the correct route.
Finished-dose manufacturing sites for LUMIGAN are also market- and time-dependent; labels sometimes name the manufacturer/packer but not always the fill-finish site.

FAQs

Who is the supplier of LUMIGAN?
In commercial terms, LUMIGAN’s supplier is the marketer/distributor organization, historically AbbVie (Allergan legacy), with local affiliates distributing in each country.
What is the active ingredient in LUMIGAN?
Bimatoprost.
Are bimatoprost API suppliers listed on LUMIGAN labels?
Often no. API sourcing typically appears in regulatory filings rather than on consumer-facing packaging.
Who manufactures the finished ophthalmic solution?
The finished dose is made by a sterile fill-finish manufacturer, which can vary across markets and over time; the exact site must be taken from the product’s regulatory label/authorization for the specific country.
How do I identify the right supplier for procurement?
Match the country-specific carton/insert to confirm the MAH/legal entity and the listed manufacturer/packer, then validate via CoA and GMP documentation from the vendor.

References (APA)

[1] FDA. (n.d.). DailyMed: LUMIGAN (bimatoprost ophthalmic solution). U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
[2] European Medicines Agency. (n.d.). Public assessment reports and product information for bimatoprost-containing products (LUMIGAN). https://www.ema.europa.eu/
[3] Government of Canada. (n.d.). Drug product database: bimatoprost and brand references (LUMIGAN). https://health-products.canada.ca/

Suppliers and packagers for lumigan

lumigan